"&#xa0;\nWritten evidence submitted by National Institute of Biological Standards and Control (BTO00005)&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nDecember 2013\n&#xa0;\nAttachments\n&#xa0;\n&#xa0;\nDr Philip Minor (NIBSC,MHRA)\nProfessor Noel Gill (PHE) \nDr Jillian Cooper (NIBSC, MHRA)\nProfessor Jean Manson (\nRoslin\n Institute)\nProfessor Richard Knight (CJDRSU)\nDr Simon Mead (MRC \nPrion\n Unit)\nDr Neil Almond (NIBSC, MHRA) \nDr David \nAnstee\n (NHSBT)\nProfessor Robert Will (CJDRSU)\nDr Maurice \nBardsley\n (VLA) \nDr Jim Hope (VLA)\nProfessor Christine Lee (Royal Free Hospital, retired)\nGill Turner (CJD Support Network)\nProfessor Marc Turner (NHSBT)\n Professor Janet \nDarbyshire\n (MRC, retired)\nDr \nMicha\n \nNuebling\n (Paul Ehrlich Institute, Germany)\nDr Joliette \nCoste\n (French Blood Transfusion Service)\nDr Stephen Lee (MHRA)\nDr Nick Andrews (PHE)\nMark \nNoterman\n (DH)\nDr Gary \nMallinson\n (NHSBT)\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\n&#xa0;\nCooper, J.K., Andrews, N., \nLadhani\n, K., \nBujaki\n, E., &amp; Minor, P.D.. Evaluation of a test for its suitability in the diagnosis of variant Creutzfeldt-Jakob disease. \nVox\n \nSanguinis\n \n2013, 105, (3) 196-204;   \nCooper, J.K., K. Ladhani, and P. Minor, Comparison of candidate vCJD in vitro diagnostic assays using identical sample sets\n.\n \nVox Sanguinis\n, 2012. \n102(2): p. 100-9;  \nJ. K. Cooper, K. \nLadhani\n &amp; P. D. Minor Reference materials for the evaluation of pre-mortem variant Creutzfeldt–Jakob disease diagnostic assays \nVox\n \nSanguinis\n (2007) \n92, 302–310\n&#xa0;&#xa0;\nThe aim of the CJD resource centre and its oversight committee is to ensure fair and appropriate access to extremely rare blood components from clinical cases of \nvCJD\n.  Samples used in these studies were generated by NIBSC in collaboration with other TSE research groups who supplied animal samples (AHVLA and \nRoslin\n); the CJD Surveillance unit and the MRC \nPrion\n clinic who provided CJD samples and the UK National Blood and Transfusion Service who provided normal donor samples.  Both test sensitivity (how little infectious material can be detected) and specificity (number of samples incorrectly scored positive) studies were performed.  \nCompleted evaluation studies:\nCompany A\nSamples  provided:\n&#xa0;\nSpiked panel sets (\nvCJD\n tissue homogenates in pooled human plasma\n              \n2006\n48 samples)\nSheep plasma samples (\nScrapie\n, BSE infected and Control; total 250)\n              \n2008\nUK blood donor plasma (1000 individuals, unfrozen, prepared \n              \n              \n2008\ndaily at NIBSC)\n              \n              \n              \n              \nPrimate plasma (BSE infected and controls; total 60)\n              \n              \n              \n2009\nUK donor plasma (Frozen set, 1000 individuals)\n              \n              \n              \n              \n2009\nVariant and Sporadic CJD plasma (3 variant, 2 sporadic)\n              \nalong\n              \n              \n2009\nWith normal donor samples (500) \n              \n              \n&#xa0;\nComplete evaluation was published in 2013:\n&#xa0;\nCooper, J.K., et al., \nEvaluation of a test for its suitability in the diagnosis of variant Creutzfeldt-Jakob disease.\n Vox Sang, 2013. \n105(3): p. 196-204.\n&#xa0;\nCompany B\n&#xa0;\n&#xa0;\nSpiked panel sets (\nvCJD\n tissue homogenates in pooled human plasma, \n              \n2009\n48 samples)\n              \nSheep plasma samples (\nScrapie\n, BSE infected and Control; total 250)\n              \n2009\nUK donor plasma (2000 samples, unfrozen (1000); frozen (1000)\n              \n              \n2011\nVariant CJD plasma (2 samples)\n              \nplus 200 normal US donor plasma \n              \n2012\nsamples\n              \n              \n              \n              \n              \n&#xa0;\nOther tests evaluated (research and commercial) \n9 groups provided with detergent-extracted plasma (48 samples)\n              \n2004\n12 groups provided with spiked plasma panel (\ncryo\n-depleted\n              \n              \n2006/2007\n pooled plasma, 48 samples)\n              \n              \n              \n              \n6 groups provided with spiked panel set using pooled whole plasma\n              \n2007/8/9/10\n&#xa0;\nFollowing evaluation of the blinded sample sets, problems with sensitivity, specificity and reproducibility were identified.  Results for these studies were published in 2012 in:\n&#xa0;\nCooper, J.K., K. Ladhani, and P. Minor, \nComparison of candidate vCJD in vitro diagnostic assays using identical sample sets.\n Vox Sang, 2012. \n102(2): p. 100-9.\n&#xa0;\nResearch groups (X5) all still currently active\nSpiked panel sets (\nvCJD\n tissue homogenates in pooled human plasma, total samples 24) \n              \n2011/12\nSheep \nbuffy\n coat preparations (\nscrapie\n and control, 12 samples sent) to\n              \n              \n              \n2013\n&#xa0;\nCommercial developers (X1\n)\nSpiked panel sets (\nvCJD\n tissue homogenates in human pooled plasma, total samples 24)\n              \n2013\n&#xa0;&#xa0;\n&#xa0;\n"